A novel immunomodulator, FTY720, prevents spontaneous dermatitis in NC/Nga mice.

Oral administration of a novel immunomodulator, FTY720 (0.1 mg/kg, once a week), completely prevented the spontaneous development of dermatitis in NC/Nga mice. It also strongly suppressed hyper IgE production in serum, as well as hypertrophy of the epidermis and the degranulation of granulocytes in the skin, all of which were observed in mice in which the dermatitis had become established. These results strongly suggest that FTY720 is a promising candidate for treatment of human atopic dermatitis.

[1]  S. Mulgaonkar,et al.  Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study , 2003, Transplantation.

[2]  K. Budde,et al.  Pharmacodynamics of FTY720, the first member of a new class of immune-modulating therapeutics in transplantation medicine. , 2003, International journal of clinical pharmacology and therapeutics.

[3]  J. Nedelman,et al.  Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  K. Budde,et al.  FTY720 alters the composition of T-lymphocyte subpopulations in the peripheral blood compartment of renal transplant patients. , 2002, Transplantation Proceedings.

[5]  Michael D. Davis,et al.  The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors* , 2002, The Journal of Biological Chemistry.

[6]  K. Budde,et al.  First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. , 2002, Journal of the American Society of Nephrology : JASN.

[7]  H. Rosen,et al.  Alteration of Lymphocyte Trafficking by Sphingosine-1-Phosphate Receptor Agonists , 2002, Science.

[8]  T. Hanano,et al.  Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. , 2000, Journal of medicinal chemistry.

[9]  L. Feng,et al.  FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. , 2000, Trends in pharmacological sciences.

[10]  K. Sugahara,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. , 1998, Journal of immunology.

[11]  H. Kataoka,et al.  FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. , 1998, Journal of immunology.

[12]  P. Askenase,et al.  Development of Atopic Dermatitis-like Skin Lesion with Ige Hyperproduction in Nc/nga Mice , 2022 .

[13]  T. Fujita,et al.  Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: Discovery of a novel immunosuppressant, FTY720 , 1995 .

[14]  T. Okumoto,et al.  Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. , 1994, The Journal of antibiotics.

[15]  S. Yoshitake,et al.  Enzyme-labeling of antibodies and their fragments for enzyme immunoassay and immunohistochemical staining. , 1983, Journal of immunoassay.